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Sub-acuteA survey conducted on the EU Notiﬁcation of New Substances (NONS) database suggested that for indus-
trial chemicals with a proﬁle of low toxicity in (sub)acute toxicity tests there is little added value to the
conduct of the 90-day repeated dose study. Avoiding unnecessary animal testing is a central aim of the EU
REACH chemicals legislation; therefore we sought to verify the proﬁle using additional data. The OECD’s
eChemPortal was searched for substances that had both a 28-day and a 90-day study and their robust
study summaries were then examined from the ECHA CHEM database. Out of 182 substances with high
quality 28-day and 90-day study results, only 18 reported no toxicity of any kind in the (sub)acute tests.
However, for 16 of these there were also no reported signs of toxicity at or close to the limit dose
(1000 mg/kg bw/d) in the 90-day study. Restricting the ‘low (sub)acute toxicity in a high quality dataset’
proﬁle to general industrial chemicals of no known biological activity, whilst allowing irritant substances,
increases the data set and improves the prediction to 95% (20 substances out of 21 substances). The low
toxicity proﬁle appears to be of low prevalence within industrial chemicals (10–15%), nevertheless,
avoidance of the conduct of a redundant 90-day study for this proportion of the remaining REACH
phase-in substances would avoid the use of nearly 50,000 animals and save industry 50 million Euros,
with no impact on the assessment of human health.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
All new and existing chemical substances that are manufac-
tured or imported in the European Union must now be registered
under EU chemicals legislation REACH (Regulation (EC) No. 1907/
2006). The difference between REACH and previous EU chemicals
legislation is that the information requirements for existing
chemicals (so called phase-in substances) are the same as for
new (non-phase-in) substances. Companies had to register all the
substances they manufacture or import in quantities above
1000 tonnes per year by 1 December 2010. All the substances they
manufacture or import in quantities above 100 tonnes per year
were also registered by 1 June 2013. A complete data package for
a REACH chemical registration at these tonnages can involve the
conduct of at least 10 different animal studies and can cost
between 800 and 1600 k Euros (for Annex IX and X, respectively)
(based on the most recent ﬁgures available; Fleischer, 2007).An example of the heavy burden of safety information required
under REACH is that for substances manufactured or imported at
levels of 100 tonnes per year or above (Annex IX requirements),
the results of both a 28-day and a 90-day repeated dose toxicity
study in rodents is required. This requirement was based on the
general assumption that the No Observed (Adverse) Effect Level
(NO(A)EL) of a substance decreases as the length of the study
increases. For substances that are produced in high quantities it
was therefore decided that a 90-day study should be required in
addition to the 28-day study. However, in order to reduce unnec-
essary animal testing, for those substances that have neither a
28-day nor a 90-day study, it is permitted to provide the results
of the 90-day study only (REACH Annex IX 8.6.2, column 1). Table 1
outlines the repeated dose and reproductive toxicity requirements
of substances being registered under REACH.
Not all existing substances will have the necessary information
requirements and it is quite possible that many substances will
actually have the results of the 28-day but not the 90-day study.
In fact, a review by the European Commission estimated that 93%
of relevant substances would not have the 90-day test prior to
Table 1
REACH requirements for repeated dose and reproductive toxicity studies.
Annex VII VIII IX X
Tonnage 1 tonne or greater 10 tonnes or greater 100 tonnes or greater 1000 tonnes or greater
Repeated dose toxicity None 28 day (most
appropriate route)
28 day (unless already conducted or the
90 day is proposed)
28 day (unless already conducted or the 90 day
is proposed)
90-day study should be proposed (most
appropriate route)
90-day study should be proposed (most
appropriate route)
Longer term studies may be proposed if serious
or severe toxicity effects of particular concern
were observed in the 28-day or 90-day study for
which the available evidence is inadequate for
toxicological evaluation or risk characterisation
A carcinogenicity study may be proposed if there
is evidence from the repeated dose study(s) that
the substance is able to induce hyperplasia and/
or preneoplastic lesions (and there is wide
dispersive use of the substance or frequent
human exposure)
Reproductive toxicity None Screening study
(OECD TG 421)
Prenatal developmental toxicity should be
proposed (most appropriate route)
Prenatal developmental toxicity should be
proposed (most appropriate route)
Two generation reproductive toxicity study
should be proposed, if the 28-day or 90-day
study indicates adverse effects on
reproductive organs or tissues
A second species prenatal developmental
toxicity should be considered and proposed
(most appropriate route)
Two generation reproductive toxicity study,
unless already provided or proposed
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regimes such as the predecessor to REACH, the Dangerous
Substances Directive (Directive 67/548/EEC Annex VIIA) and the
voluntary US High Production Volume Challenge Programme only
required the 28-day study within the basic data package. Many
REACH registrants are therefore now in the position of having to
submit ‘proposals’ to conduct 90-day studies on their substance
if the test cannot be waived for other reasons (read across, expo-
sure based arguments, etc.; see Annex XI of REACH for adaptations
to the standard testing regime).
Testing proposals must be submitted, not the test result,
because REACH says that a proposal for tests required under Annex
IX or X, such as the 90-day study, must be ﬁrst evaluated by the
agency responsible – the European Chemicals Agency (ECHA) –
before it is conducted. This is a test reduction measure put in place
to allow third parties to notify ECHA that they have existing infor-
mation on the substance, thereby avoiding duplicate animal stud-
ies. Testing proposals are published on the ECHA website for a
45 day comment period and then a decision is made via a bureau-
cratic process that can take at least a year.
In this period of intense data collection to satisfy REACH
requirements it is crucial to seek to maximise efﬁciency, not only
of animals but of cost to the industry at large. Despite the animal
reduction measures written into the legislation, within a complete
REACH submission for which the results of several toxicological
studies of different durations and covering a range of endpoints
are required, it is entirely possible that there will be tests that
are less useful than others. Due to the similar nature of the
repeated dose tests – the only difference being duration of the dos-
ing – it is feasible that there may be some element of duplication to
the conduct of both the 28-day and the 90-day study for example.
Identifying studies that add little in terms of information on the
hazardous properties of the substance, and are in effect ‘redun-
dant’, is a relatively easy way to reduce animal testing and costs
to industry, without adversely impacting on the level of protection
of human or environmental health. Examples of where this
approach has proved fruitful include a review of the need for der-
mal acute toxicity studies for industrial chemicals and pesticides
(Creton et al., 2010) and a review of the need for single dose acute
toxicity studies for medicinal compounds (Robinson et al., 2008)
and for industrial chemicals (Chapman et al., 2010) all by the UKNational Centre for the 3Rs, a review of the need for the second
generation in reproductive toxicity studies by the Dutch National
Institute for Public Health and the Environment (Janer et al.,
2007), and a review of the need for carcinogenicity studies for
medicinal products by the German Federal Institute for Drugs
and Medical Devices (Friedrich and Olejniczak, 2011) and also by
the US drug industry (Sistare et al., 2011).
Based on their experience with the Notiﬁcation of New Sub-
stances (NONS) system – the chemical registration system that
predated REACH – some members of the UK Competent Authority
for REACH [the Health and Safety Executive (HSE)] felt that there
may be redundancy in the 90-day repeated dose toxicity study.
This is because when they reviewed NONS dossiers with low
toxicity in the 28-day study they consistently found that the
90-day study also demonstrated low toxicity. To demonstrate their
hypothesis, the HSE performed a systematic analysis of the NONS
database, which was not publicly available at the time. They found
that out of 110 substances with results for both 28-day and 90-day
studies via the same exposure route, 17 substances (15%) were
identiﬁed that had a NO(A)EL close to or greater than 1000 mg/
kg bw/d in the 28-day study. In all these substances the 90-day
NO(A)EL was also equivalent to or higher than the limit dose of
1000 mg/kg bw/d. The limit dose of 1000 mg/kg bw/d is a
pragmatic value introduced to prevent the use of excessive dose
levels in toxicity studies, which would be likely to result in effects
of no relevance to the human risk assessment. The results of their
analysis therefore strongly suggested that there was no added
value to the conduct to the 90-day study in these situations, with
no margin of error. As a precautionary approach they recom-
mended that all acute endpoints including acute toxicity (by any
route), mutagenicity, skin sensitisation and skin and eye irritation
should also be negative for the substance to satisfy the ‘low toxic-
ity proﬁle’. However, this would have reduced their dataset to 14
substances with obviously no improvement to be gained in
predictivity.
The HSE presented their results to the Member State Committee
(MSC) at the ECHA in January 2011 (HSE, 2011). The MSC is ECHA’s
committee that agrees on the need for new toxicity tests when
conducting compliance checks of registration dossiers and testing
proposals made by registrants who have already identiﬁed that
they have a data gap. The MSC members expressed interest in
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the hypothesis and the use of potentially low quality 28-day
studies to waive what is generally considered to be the more
robust 90-day study.
Unfortunately, the ECHA or other Member States have not, to
date, investigated this issue further using other databases available
to them. Since the HSE proposal, however, the database of regis-
tered substances under REACH has been populated with informa-
tion; primarily on Annex X substances produced in excess of
1000 tonnes per year. This public database called ECHA CHEM
(available from the ECHA website www.echa.europa.eu) is Euro-
pean Chemicals Agency’s dissemination portal with information
on chemical substances registered under REACH and contains
information on the composition and use of the substance as well
as the ‘robust study summaries’ of the toxicity tests included in
the registration dossier.
In the interests of avoiding the future conduct of unnecessary
animal tests we therefore sought to substantiate the HSE hypothe-
sis using additional substances now within the ECHA CHEM data-
base. Our hypothesis was the same as the HSE; where a substance
has both a 28-day and a 90-day study result and exhibits a proﬁle
of low toxicity in the 28-day study and other acute tests, the
90-day study result will also be ‘low toxicity’ (NOAEL deﬁned as
close to or greater than 1000 mg/kg bw/d). In order to respond to
the reservations of some of the MSC members we applied strict
inclusion and exclusion criteria to the dataset to ensure it was of
high quality.2. Method
2.1. Initial selection of data set
We used the OECD’s eChemPortal (www.echemportal.org) to
search for substances for which there was both a 28-day and a
90-day study. The eChemPortal is an effort of the Organisation
for Economic Co-operation and Development (OECD) in collabora-
tion with the European Commission, ECHA, the United States,
Canada, Japan, the International Council of Chemical Associations,
the Business and Industry Advisory Committee, the World Health
Organization’s International Program on Chemical Safety, the
United Nations Environment Programme and environmental non-
governmental organisations. eChemPortal provides free public
access to information on properties of chemicals. It allows simulta-
neous searching of reports and datasets by chemical name and
number and by chemical property. At the time of the survey, the
participating databases with information on chemical properties
were CCR (Canadian Categorization Results), ECHA CHEM, J-CHECK
(Japan CHEmicals Collaborative Knowledge database) and the
OECD SIDS IUCLID (OECD Existing Chemicals Screening Informa-
tion Data Sets (SIDS) Database). The eChemPortal was used for
the initial search as it is not yet possible to search for substance
by property type in the ECHA CHEM database. However, since
ECHA CHEM is the main database with information on substance
properties, a property search in eChemPortal is currently effec-
tively a search of the ECHA CHEM database. At the time of the sur-
vey it was not easy to do a combined query in eChemPortal so we
chose to search ﬁrstly for substances with a 90-day study, since
this was regarded to be the least common of the two repeated dose
tests.
At the time of our analysis, according to ECHA at their annual
stakeholder day in May 2012 the database was populated with
the data from approximately 4335 substances, including most of
the Annex X substances registered by December 2010. There had
been some delay to publication of information on these substances
by ECHA and further delay to the publication of this paper wasdone so as not to preclude any decisions they would make on
the information needs of some of these (see Section 4.10). The
search was conducted as follows:
1. Selected ‘‘Chemical Property Data Search’’.
2. Under the subheading ‘‘Toxicological Information’’, selected
‘‘repeated dose toxicity: oral’’.
3. For the search criteria in the Query Block, under ‘‘study result
type’’ dropdown menu, checked the box next to ‘‘experimental
result’’ (left all other boxes unchecked).
4. Under ‘‘Test guideline, Guideline’’ dropdown menu, checked the
boxes next to the following guidelines (i.e. all 90-day oral stud-
ies in case any were misreported) and added them to the search
criteria:
a. EPA OPP 82-1 (90-day oral toxicity)
b. EPA OPPTS 870.3100 (90-day oral toxicity in rodents)
c. EPA OPPTS 870.3150 (90-day oral toxicity in non-rodents)
d. EPA OTS 798.2650 (90-day oral toxicity in rodents)
e. EU Method B.26 (sub-chronic oral toxicity test: repeated
dose 90-day oral toxicity study in rodents)
f. EU Method B.27 (sub-chronic oral toxicity test: repeated
dose 90-day oral toxicity study in non-rodents)
g. OECD guideline 408 (repeated dose 90-day oral toxicity in
rodents)
h. OECD guideline 409 (repeated dose 90-day oral toxicity in
non-rodents)
5. Selected ‘‘Save’’ to save search criteria then selected Execute
Query.
eChemPortal returned a total of 964 substances that reportedly
had experimental data for a 90-day study in any species by the oral
route. This number is not representative of the actual number of
substances with 90-day study results as we subsequently found
that eChemPortal cannot recognise test result data from other
information such as ‘test proposed’ or ‘read across’.
2.2. Inclusion criteria
The dataset generated under this search was then manually
analysed in order to identify those substances which actually had
experimental data on the substance itself for both the 28-day
and 90-day study by the oral route, in rats. This involved manually
clicking through from the eChemPortal search result to the record
for the substance, which in all cases was located in the ECHA CHEM
database. Substances for which there were no 28-day or 90-day
studies on the substance itself, i.e. read across was used or no
actual studies were included, were rejected at this stage. This
reduced the dataset to 182 substances with both 28-day and
90-day studies by the oral route in rats.
2.3. Exclusion criteria
2.3.1. Key 28 day study
The dataset was then reviewed to strictly exclude all those that
had a NOAEL reported to be less than 1000 mg/kg bw/d in their key
28-day study. Where the NOEL (only) was reported this had to also
be 1000 mg/kg bw/d (the NOAEL would be at least this value in
these cases). Where the NOAEL was 1000 mg/kg bw/d and the
NOEL was reported to be a lower value, then such substances
would also be excluded. Substances with more than one key
28-day study were rejected if any rodent study did not conform
to this (in practice this was rare). This reduced the dataset to 34
substances. It is important to note that in this survey the reports
of the registrant regarding the NO(A)EL value were accepted, i.e.
there was no reanalysis on our part of the signiﬁcance of the bio-
logical results and respective adjustment of the NO(A)EL.
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The dataset was then further reduced in order to remove sub-
stances with poor quality datasets. These were deﬁned as where
the 28-day and 90-day studies were:
 Not equivalent to the corresponding OECD guideline (TG 407
(28-day repeated dose) or TG 408 (90-day repeated dose)) in
terms of duration, species (rats), numbers of animals or main
parameters measured. Studies were included if they measured
body weight, clinical signs, mortality, histopathology of at least
all major organs, clinical chemistry and haematology. Neurobe-
havior, immunology, urinalysis, ophthalmology were optional
since these were not included in the original 1981 versions of
OECD TG 407 and 408. Range-ﬁnding studies of shorter duration
or reduced numbers of animals, the combined repeated dose/
reproductive toxicity screening study (OECD TG 422) or pub-
lished studies that looked at limited parameters were excluded.
 Not conducted up to the limit dose (1000 mg/kg bw/d).
 Conducted prior to 1981 (the date both OECD guidelines were
created).
 Apparently equivalent to OECD TG 407 or TG 408 but given a
Klimisch score 3 or 4 for whatever reason (A score of 3 or 4 indi-
cates that there are problems with the data quality and report-
ing as well as not being GLP compliant, Klimisch et al., 1997).
For the purposes of this review, the 90-day result also had to
conform to this. One substance (EC 931-203-0) was removed
because there had been a bacterial infection in the test animals
in the 90-day study such that the registrant was not sure of the
biological signiﬁcance of the effects seen. This further reduced
the dataset to 25 substances with high quality 28-day and
90-day study summaries.
2.3.3. Acute toxicity proﬁle
Substances were further excluded if they did not have test data
(no instances) or had test data that met the criteria for classiﬁca-
tion for:
 Acute toxicity (by any route) (0 substances).
 Irritation (skin or eye) (5 substances).
 Skin sensitisation (2 substances, one of which was also a mild
irritant).
 Genotoxicity (a positive alert in vitro that was not followed up
with a negative in vivo result) and/or a positive in vivo result
(0 substances).
The acute toxicity proﬁle for each substance was reviewed
using the information provided in the ECHA CHEM database. The
registrant’s summary reports were accepted as to whether they
met the criteria for classiﬁcation. The Classiﬁcation and Labelling
(CLP) database on the ECHA website was not used for this purpose
as at the time it provided inconsistent information on the classiﬁ-
cation of substances. The ﬁnal dataset of substances with low
(sub)acute toxicity proﬁles with high quality datasets was 18 sub-
stances (10% of 182).
The 90-day study result was then reviewed to determine if
the NOAEL was reported to be close to or greater than 1000 mg/
kg bw/d.3. Results
25 substances were reported to have a NOAEL in the 28-day
study equal to or greater than 1000 mg/kg bw/d, see Table 2.
These substances did not appear to have any common features,
some were simple molecules, and others were complex UVCBs(of unknown or variable composition or biological origin).
[Physical chemical properties for each substance can be found
by typing in the EC number into the ECHA CHEM database at
www.echa.europa.eu]. They included:
 Natural dietary components or substances that are metabolised
to dietary components (e.g. EC 205-538-1);
 Endogenous molecules (e.g. EC 211-519-9);
 Simple mineral salts (e.g. EC 232-094-6).
Five of the substances were reported to be skin or eye irritants
(only) and two were reported to be skin sensitisers (one of which
was also a mild skin irritant). Out of the remaining 18 substances
with a ‘low (sub)acute toxicity proﬁle’ (i.e. no positive acute toxic-
ity results), 16 (89%) also had a reported NOAEL close to or greater
than 1000 mg/kg bw/d in the 90-day study.
For two of the 16 substances the NOAEL was not reported to be
1000 mg/kg bw/d but was very close. Substance EC 203-490-6 was
reported with NOAEL of >812 6 4113 mg/kg bw/d, with no adverse
effects at the highest dose of 5% in diet. For substance EC 211-519-9,
the reported NOAEL was 968 mg/kg bw/d in females, 914 mg/
kg bw/d in males (1.5% in diet). Minor effects were seen at the next
dose which was 3000 mg/kg bw/d. We considered that these two
substances could reasonably be considered to be of low toxicity.
For the two remaining substances, for various reasons, the
reported NOEAL was not close to 1000 mg/kg bw/day.
A NOAEL of 500 mg/kg bw/d was reported for a 90-day rat study
for substance EC 231-710-0, based on effects on clotting parame-
ters at the highest dose level of 2000 mg/kg bw/d. These parame-
ters were also investigated in the 28-day study but were not
reported to have been affected by treatment and the NOAEL in
the 28 day study was reported to be 2000 mg/kg bw/d (the highest
dose level tested). The substance is vitamin E acetate and is known
to be biologically active. It exists as a number of stereoisomers and
different forms of the substance are known to have varying biolog-
ical potency. The material tested in the 28-day and 90-day studies
appears to have been of different composition in terms of stereo-
isomer content. The material used in the 90-day study is known
to be of higher potency than that used in the 28-day study, poten-
tially explaining the apparent discrepancy in the results of these
studies.
A 90-day toxicity study performed in the rat with substance EC
619-383-6 reported a NOAEL of 1000 mg/kg bw/d for females but a
NOAEL of 250 mg/kg bw/d for males. The substance was shown to
cause renal toxicity in both sexes at the highest dose level of
1905 mg/kg bw/d and also in one of ten male rats at 1000 mg/
kg bw/d. Similar effects were apparent in rats of both sexes at
the highest dose level of 2500 mg/kg bw/d in the 28-day studies,
but were not seen in either sex at 1000 mg/kg bw/d. A NOAEL of
1000 mg/kg bw/d was therefore proposed for the 28-day study.
While a simple comparison of NOAEL values indicates an increase
in toxicity following 90-day exposure compared to 28-day expo-
sure, more detailed analysis of the data shows that the increase
in toxicity is in fact marginal, and may reﬂect biological variation.
This substance is however used as a pesticide so is considered to be
biologically active.
The NOAEL in the 90-day study was also equal than or greater
than 1000 mg/kg bw/d for four of the ﬁve skin/eye irritants. For
one (EC 203-874-3, 2,20-sulfanediyldiethanol or thiodiglycol), the
registrant reported the NOAEL to be 500 mg/kg bw/d because
minor effects on body weight and kidney weight were seen at
the next dose which was ﬁve times the limit dose; 5000 mg/
kg bw/d. The study does not deﬁnitely demonstrate an absence
of toxicity at 1000 mg/kg bw/d as this dose level was not tested;
however it would seem unlikely that any toxicity would have been
seen at this dose level.
Table 2
Details of the 25 substances identiﬁed to have a NO(A)EL of 1000 mg/kg bw/d in an adequate quality 28 day repeated dose toxicity test. More details on the substances can be found via ECHACHEM database www.echa.europa.eu.
EC No. 28 day result 90 day result Skin sensitisation Acute tox – oral Acute tox –
dermal
Acute tox –
inhalation
Skin
irritation
Eye
irritation
Mutagenicity
– in vitro
Mutagenicity
– in vivo
Comments
201-148-0 (1985) 90 day with interim
sacriﬁce at 28 days
NOAEL = 1000 mg/kg bw/
d; (1983) Exp NS:
LD0P 610 mg/kg bw/d
(highest dose tested), no
mortalities observed, no
details on signs of systemic
toxicity to determine
NOAEL
(1991) NOAEL = 1000
mg/kg bw/d; (1985)
NOAEL > 1450
mg/kg bw/d (highest dose
tested)
QSAR WoE: not
sensitising
LD50 = 3350 mg/
kg bw in females,
>2830 mg/kg bw
in males – toxicity
category 5
LD50 = 2460 mg/
kg bw in
females,
>2000 mg/kg bw
in males –
toxicity category
4
LC50 > 18.18 mg/L
air, 6000 ppm
Exp WoE:
mixed:
corrosive/
not
irritating
Irritating –
category 1
(irreversible
effects on
the eyes)
Negative –
Ames test/
mammalian
cell mutation
assay/in vitro
mammalian
micronucleus
test
Negative –
micronucleus
assay
Skin and eye
irritant
203-490-6 (2001) NOAEL > 5771 mg/
kg bw/d (highest dose
tested)
(2001) No NOAEL
identiﬁed – between >
812 6 4113 mg/kg bw/d,
at highest dose 5% in diet
no adverse effects were
seen. Slight effect: some
hepatic and
haematological changes
Not sensitising –
GPMT
LD50 = 11179 mg/
kg bw – not
classiﬁed
N/A N/A Not
irritating
Not
irritating
Negative –
bacterial gene
mutation
assay/in vitro
MCAT
Negative –
micronucleus
assay
90-day NOAEL
close to
1000 mg, large
dose ranges
203-874-3 (1993) NOAEL = 1000 mg/
kg bw/d (highest dose)
(1997) NOAEL = 500 mg/
kg bw/d,
LOAEL = 5000 mg/kg bw/
d (highest dose) (effects
on body weight and
kidney weight at highest
dose)
Not sensitising –
GPMT
LD50 = 10000 ll/
kg bw, 11800 mg/
kg bw
LD50 = 23600
mg/kg bw
No mortality in male
and female rats
exposed to saturated
vapour at 20 C for
8 h
Not
irritating
Slightly
irritating;
very mild,
reversible
effects
Negative –
Ames test/
mammalian
cell gene
mutation
assay/in vitro
MCAT
Negative –
micronucleus
assay
Slight eye
irritant, some
effects in 90-day
but large dose
ranges
205-538-1 (1997) NOAEL = 4800
mg/kg bw/d in females,
5100 mg/kg bw/d in males
(1997)
NOAEL = 5300 mg.kg
bw/d in males, 4900 mg/
kg bw/d in females
(2007) NOAEL = 3170 mg/
kg bw/d in males,
3620 mg/kg bw/d in
females
(2007) NOAEL = 1500 mg/
kg bw/d in dogs
Not sensitising –
GPMT
LD50 = 17.3 g/
kg bw in males,
15.8 g/kg bw in
females – not
classiﬁed
LD50 > 2000 mg/
kg bw – not
classiﬁed
N/A Not
irritating
Not
irritating
Negative –
Ames test/
in vitro
chromosome
aberration
test
Negative –
micronucleus
assay
207-312-8 (1983) NOAEL = 2000 ppm
in diet, at the next higher
level of 20,000 ppm only
slight changes of doubtful
toxicological signiﬁcance
(1991) NOEL = 900 mg/kg/
d (dogs)
(1985)
NOAEL > 24000 ppm
(1991) NOAEL 2.5% in diet
Not sensitising –
GPMT
LD50 > 10,000 mg/
kg bw –
Practically
nontoxic
LD50 > 2000
mg/kg bw –
relatively
harmless
LC50 > 259 mg/m3
(dust) (highest dose
tested)
Not
irritating
Not
irritating
Negative –
Ames test
N/A
208-764-9 (1990) NOAELP 1500 mg/
kg bw/d
(1991)
NOAELP 1000 mg/
kg bw/d (highest dose
tested)
Not sensitising –
LLNA/GPMT
LD50 > 5000 mg/
kg bw – not
classiﬁed
LD50 > 2000 mg/
kg bw – not
classiﬁed
LC50 = 8.67 mg/L
(aerosol) – toxicity
category 3;
mortality seen at
high concentrations
Not
irritating
Not
irritating
Negative –
Ames test/
mammalian
cell gene
mutation
assay/in vitro
MCAT
Negative –
micronucleus
assay/
unscheduled
DNA
synthesis
Mildly acutely
toxic by aerosol
211-519-9 (1998) NOEL = 1940 mg/
kg bw/d in females,
1965 mg/kg bw/d in males
(2% in diet) (highest dose
tested)
(2003) NOAEL = 968 mg/
kg bw/d in females,
914 mg/kg bw/d in males
(1.5% in diet) (next
highest dose 3000 mg/
kg bw/d, minor effects
seen)
Not sensitising –
GPMT
LD50 = 10600 mg/
kg bw –
practically
nontoxic
N/A LC50 > 5.51 g/m3 –
practically nontoxic
Not
irritating
Not
irritating
Negative –
Ames test/
mammalian
cell gene
mutation
assay/in vitro
chromosome
aberration
test
N/A
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213-879-2 (2005) NOAEL = 1000 mg/
kg bw/d (highest dose
tested)
(2006) NOAEL = 1000
mg/kg bw/d (highest dose
tested)
Not sensitising –
GPMT/LLNA
LD50 > 10000 mg/
kg bw – not
classiﬁed
LD50 > 2000 mg/
kg bw – not
classiﬁed
LC50 > 3.1 mg/L air –
not classiﬁed
Not
irritating
Not
irritating
Negative –
Ames test/
mammalian
cell gene
mutation
assay/in vitro
chromosome
aberration
test
Negative –
micronucleus
assay
221-424-4 (2005) NOAEL = 1000 mg/
kg bw/d (highest dose
tested)
(2009) NOAEL = 1000 mg/
kg bw/d (highest dose
tested)
Not sensitising –
LLNA/GPMT
LD50 > 5000 mg/
kg bw – not
classiﬁed
LD50 > 2000
mg/kg bw – not
classiﬁed
LC50 > 3.1 mg/L
(dust) – not
classiﬁed
Not
irritating
Not
irritating
Negative –
Ames test/
mammalian
cell gene
mutation
assay
Negative –
micronucleus
assay
231-493-2 (1987) NOAEL = 4160 mg/
kg bw/d (highest dose
tested), only reversible
effects
(1990) NOAEL = 10% in
diet (10,0000 ppm;
10,000 mg/kg bw/d)
(highest dose tested)
Not sensitising –
GPMT
LD50 > 5000 mg/
kg bw –
practically
nontoxic
LD50 > 2000
mg/kg bw –
relatively
harmless
LC50P 4.9 mg/L air
(dust)
Not
irritating
Slightly
irritating
Negative –
Ames test/
mammalian
cell gene
mutation
assay/in vitro
MCAT
Negative –
micronucleus
assay/
Drosophila
SLRL test
Slight eye
irritant
231-710-0 (1999) NOAEL = 2000 mg/
kg bw/d, some effects were
seen but dismissed as not
of toxicological
signiﬁcance
(1986) NOAEL = 500 mg/
kg bw/d (severe toxic
effects at next level of
2000 mg/kg bw/d)
(1982) NOAEL > 360 mg/
kg bw/d (highest dose
tested in dogs)
(2000) NOAEL > 2000 mg/
kg bw/d (highest dose
tested in minipig)
Not sensitising –
photoallergenicity
test/Draize test
LD50 > 10000 mg/
kg bw – not
classiﬁed
LD50 > 3000
mg/kg bw – not
classiﬁed
N/A Not
irritating
Not
irritating
Negative –
Ames test/
in vitro
chromosome
aberration
test
Negative –
micronucleus
assay
Vitamin E
acetate, species
differences in
90-day results
232-094-6 (2010) NOAEL > 1000 mg/
kg bw/d
(2009) NOAEL > 1500 mg/
kg bw/d (highest dose
tested)
(1993) NOAEL = 5%
(12830 mg/kg bw/d) in
females, 2.5% (5410 mg/
kg bw/d) in males
(2000) NOAEL > 0.5%
(308 mg/kg bw/d)
Not sensitising –
GPMT
LD50 > 5000 mg/
kg bw – not
classiﬁed
LD50 > 2000 mg/
kg bw – not
classiﬁed
N/A Not
irritating
Not
irritating
Negative –
mammalian
cell gene
mutation
assay/in vitro
MCAT
N/A
232-482-5 (1985) NOAEL = 1% in feed
(highest dose tested)
(1991) NOAEL = 2500 mg/
kg w/d (highest dose
tested)
(1982) NOAEL = 1% in diet
(1989)
NOAEL = 10,000 ppm for
male and female rats
(which corresponds to
714.0 and 831.0 mg/
kg bw/d (Ester Gum-CGR)
and 713.5 and 815.0 mg/
kg bw/d (Ester Gum-PGR)
in males and females,
respectively)
Not sensitising –
GPMT
LD50 > 2000 mg/
kg bw - not
classiﬁed
LD50 > 5000 mg/
kg bw – not
classiﬁed
N/A Not
irritating
Slightly
irritating
Read across:
negative –
Ames test/
mammalian
cell gene
mutation
assay/in vitro
MCAT
N/A Slight eye
irritant
235-186-4 (2004)
NOAEL = 2214.5 mg/
kg bw/d, effects on body
weight at 4228.5 mg/
(2004)
NOAEL = 1695.7 mg/
kg bw/d, effects on body
weight seen at
Not sensitising –
GPMT
LD50 > 1410 mg/
kg bw
LD50 > 2000 mg/
kg bw – read
across
N/A Not
irritating
Irritating Negative –
Ames test/
mammalian
cell gene
Negative –
micronucleus
assay
Eye irritant
(continued on next page)
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Table 2 (continued)
EC No. 28 day result 90 day result Skin sensitisation Acute tox – oral Acute tox –
dermal
Acute tox –
inhalation
Skin
irritation
Eye
irritation
Mutagenicity
– in vitro
Mutagenicity
– in vivo
Comments
kg bw/d 3372.6 mg/kg bw/d mutation
assay/in vitro
chromosome
aberration
test
247-148-4 (1997) NOAEL = 1000 mg/
kg bw/d (highest dose
tested), although some
effects on the liver
(2001) NOAEL = 1000 mg/
kg bw/d (highest dose
received)
Not sensitising –
GPMT/LLNA
LD50 > 10000
mg/kg bw – not
classiﬁed
LD50 > 20000
mg/kg bw – not
classiﬁed
LC50 > 202.14 mg/L
air – not classiﬁed
Not
irritating
Not
irritating
Negative –
Ames test/
mammalian
cell gene
mutation
assay/in vitro
chromosome
aberration
test
Negative –
micronucleus
assay
Substance is
identiﬁed as PBT
and is on the
Authorization
list for
bioaccumulation
259-910-3 (1990) NOAEL = 1000 mg/
kg bw/d
(1992) NOAEL = 1000 mg/
kg bw/d
Not sensitising –
Buehler test
LD50 = 3100
mg/kg bw in
males, 2600 mg/
kg bw in females –
not classiﬁed
LD50 > 2000
mg/kg bw – not
classiﬁed
N/A Not
irritating
Not
irritating
Negative –
Ames test
Negative –
micronucleus
assay
284-366-9 (1991) NOELP 1250 mg/
kg bw/d (highest dose
tested)
(1992) NOAEL > 1000 mg/
kg/day (highest dose
tested)
Not sensitising –
GPMT
LD50 > 5000
mg/kg bw –
practically
nontoxic
LD50 > 2000 mg/
kg bw –
practically
nontoxic
N/A Not
irritating
Not
irritating
Negative –
Ames test/
in vitro
chromosome
aberration
test
N/A On CoRAP list
for PBT/
environmental
concerns
425-220-8 (1997) NOAEL = 1000 mg/
kg bw/d, NOEL = 1000 mg/
kg bw/d (oral) (highest
dose tested)
(2010)
NOAELP 1000 mg/
kg bw/d (highest dose
tested)
Not sensitising –
GPMT
LD50 > 2000
mg/kg bw – not
classiﬁed
LD50 > 2000 mg/
kg bw – not
classiﬁed
N/A Not
irritating
Not
irritating
Negative –
Ames test/
mammalian
cell gene
mutation
assay/in vitro
chromosome
aberration
test
N/A
475-290-9 (1992) NOEL > 1000 mg/
kg bw/d
(2008) NOAEL = 3601 mg/
kg bw/d in females,
3129 mg/kg bw/d in
males
Not sensitising –
GPMT
LD50 > 5110 mg/
kg bw – not
classiﬁed
LD50 > 2000 mg/
kg bw – not
classiﬁed
N/A Not
irritating
Not
irritating
Negative –
Ames test
N/A
500-033-5 (1984) NOEL > 1000 mg/
kg bw/d
(2000) NOAEL = 50 mg/
kg bw/day, decreased
body weights at doses
higher than 250 mg/
kg bw/d
Sensitising: LLNA LD50 > 15000 mg/
kg bw – toxicity
category 5
LD50 > 20 mL/
kg bw – toxicity
category 4
LC0 = 0.000008 ppm
(saturated
atmosphere)
Slightly
irritating
Not
irritating
Positive –
mammalian
cell gene
mutation
assay,
negative –
Ames test
Negative –
dominant
lethal assay
Skin sensitizer
and skin irritant
500-183-1 (1994) NOAEL = 6245 mg/
kg bw/d in males,
6771 mg/kg bw/d in
females
(1994) NOAEL = 1000 mg/
kg bw/d
(1995)
NOAEL = 4159.4 mg/
kg bw/d males,
4619.9 mg/kg bw/d
females
Not sensitising –
GPMT
LD50 > 5000 mg/
kg bw – not
classiﬁed
Read across:
LD50 > 2000 mg/
kg bw – not
classiﬁed
LC50 > 5.2 mg/L air –
not classiﬁed
(aerosol)
Not
irritating
Not
irritating
Negative –
Ames test
Read across:
negative –
micronucleus
assay
619-383-6 (1988) NOAEL = 1000 mg/
kg bw/d (toxicological
(1987) NOAEL = 1000 mg/
kg bw/d (females),
Not sensitising –
GPMT
LD50 > 5000
mg/kg bw –
LD50 > 2000
mg/kg bw –
Effect level = 1.2 mg/
L air – not classiﬁed
Not
irritating
Not
irritating
Negative –
Ames test/
Negative –
micronucleus
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effects at 2500 mg/kg bw/
d)
250 mg/kg bw/d (males);
effects on kidneys seen in
one male at 1000 mg/kg/
bw/d
(1988) NOEL = 1000 mg/
kg bw/d, LOEL = 5000 mg/
kg bw/d (mice)
(1989) NOAEL 500 mg/
kg/day (females), no
NOAEL identiﬁed for
males, effects on kidneys
and liver at 500 mg/
kg bw/d (dogs)
practically
nontoxic
acute dermal
toxicity
classiﬁed as low
in vitro
chromosome
aberration
test
assay
700-073-5 (2009) NOAEL = 2000 mg/
kg bw/d (highest dose
tested)
(2010)
NOAELP 2000 mg/
kg bw/d (highest dose
tested)
Not sensitising –
LLNA
LD50 > 2300 mg/
kg bw –
practically
nontoxic
N/A N/A Not
irritating
Not
irritating
Negative –
Ames test/
mammalian
cell gene
mutation
assay
Negative –
micronucleus
assay
931-269-0 (2008) NOAEL = 1000 mg/
kg bw/d (highest dose)
(1999) NOAEL = 1000 mg/
kg bw/d, some
haematological effects at
this dose which were
dismissed
Not sensitising –
GPMT
LD50 > 2000
mg/kg bw – not
classiﬁed
LD50 > 2000
mg/kg bw – not
classiﬁed
Read across:
LC50 > 2100 mg/m3
air – not classiﬁed
Not
irritating
Not
irritating
Negative –
Ames test/
in vitro MCAT
Negative –
micronucleus
assay
932-215-9 (1993) NOEAL = 51100 mg/
kg bw/d in males,
5221 mg/kg bw/d in
females
(1992) 3 mL/kg bw/d
(2003) NOAEL = 3000 mg/
kg bw/d in males,
3300 mg/kg bw/d in
females
2/3 LLNA test were
sensitising
probably should
be classiﬁed
LD50 > 5000
mg/kg bw
LD50 > 2000
mg/kg bw
N/A Not
irritating
Not
irritating
Negative –
Ames test/
in vitroMCAT/
mammalian
cell gene
mutation
assay
Negative –
micronucleus
assay
Possible skin
sensitiser
Abbreviations: GPMT, guinea pig maximisation test; LLNA, local lymph node assay; MCAT, mammalian chromosome aberration test; NOAEL, No Observed Adverse Effect Level; NOEL, No Observed Effect Level.
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4.1. Overall result
This is the ﬁrst study we are aware of that utilises the ECHA
CHEM database to evaluate the utility of a toxicological endpoint
from the perspective of the 3Rs.
Out of a total of 182 substances with a 28-day and a 90-day
study via the oral route in rats, a total of 18 substances had a
NOAEL in a high quality 28-day study of equal to or higher than
1000 mg/kg bw/d and a proﬁle of low toxicity in all other acute
tests. This constituted just 10% of the 182 substances with both
studies. All studies had a Klimisch score of 1 or 2 which indicates
that they are either GLP compliant guideline studies or otherwise
high quality reports. Most of the substances were excluded
because they had a reported NOAEL of less than the limit dose,
or the NOAEL (or NOEL) could not be identiﬁed. A small proportion
of these had reported no toxic effects at the highest dose level
tested which happened to be less than 1000 mg/kg bw/d. On a pre-
cautionary basis it was decided to exclude these substances, as the
reasons for not giving the limit dose were not available. As one
might expect, none of the substances with low toxicity in a high
quality 28-day study were reported to be acutely toxic either. This
was also found in the HSE NONS study.
In 89% of cases where the substance had a proﬁle of low toxicity
in sub-acute (28-day) studies the substance also had a proﬁle of
low toxicity in the subchronic (90-day) study, that is, a 90-day
study NOAEL close to 1000 mg/kg bw/d (16 out of 18 substances).
The limit dose of 1000 mg/kg bw/d is a pragmatic value introduced
to prevent the use of excessive dose levels in toxicity studies,
which would be likely to result in effects of no relevance to the
human risk assessment. The conduct of the 90-day study in these
cases did not add to the hazard assessment of the substance.
On a precautionary basis, skin and eye irritants (as well as two
skin sensitisers) were excluded from the ‘low toxicity proﬁle’ as
suggested by the HSE NONS review. However, four out of ﬁve sub-
stances with some degree of skin or eye irritation but showing low
toxicity in the 28-day study also showed low systemic toxicity in
the 90-day study. One substance had an equivocal result but could
also be considered as showing low toxicity in the 90-day study. In
the HSE NONS review, in fact, permitting substances with any alert
for mutagenicity, skin sensitisation and skin irritation did not
change the 100% prediction of low toxicity in the 90-day study.
Including substances with irritation potential expands the propor-
tion of substances for which the ‘low (sub)acute toxicity proﬁle’
applies and does not affect the prediction. Irritation effects do
not seem to necessarily indicate biological activity and could be
a result of pH or mechanical effects (especially for eye irritation).
In addition, local (site of contact) irritant effects tend to be disre-
garded in oral studies performed using oral (gavage or dietary)
exposure as not of relevance to the risk assessment. It is also worth
noting that the results of eye irritation tests in vivo in particular
have been shown to be notoriously unreliable and inaccurate
(Ohno et al., 1999; Lordo et al., 1999; Weil and Scala, 1971) and
there is therefore a risk that genuinely non-irritant (and non-toxic)
substances may be unnecessarily excluded from the ‘low toxicity’
rule by relying on the results of this particular in vivo test.
The results from the two substances where the reported 90-day
NOAEL was not close to 1000 mg/kg bw/d did not in fact disprove
the low toxicity hypothesis as the conclusions made by the regis-
trant may have been too conservative, due to different stereoiso-
mers being tested or the wide dose ranges used. However, these
substances could have been considered in advance to be ‘biologi-
cally active’; substance EC 231-710-0 is actually vitamin E acetate
and EC 619-383-6 is a pesticide. On a conservative basis from thisanalysis it could be argued that such substances should not be con-
sidered to ﬁt the ‘low toxicity proﬁle’ anyway.
4.2. Suggested criteria for determination of the ‘low (sub)acute toxicity
with high quality data’ proﬁle
We therefore conclude that, if a substance fulﬁls the following
criteria for a proﬁle of ‘low (sub)acute toxicity with high quality
data’, then the 90-day study is likely to be redundant:
 Experimental data equivalent to OECD TG 407 28-day oral tox-
icity in rats, on the substance itself, conducted in 1981 or later,
with Klimisch reliability score 1 or 2 and conducted to the limit
dose (1000 mg/kg bw/d) or beyond, with a study result reported
to be a NOAEL of 1000 mg/kg bw/d or higher.
 The substance is not reported to be mutagenic or a skin sensitis-
er or acutely toxic by any route and there are adequate data to
support this (i.e. any positive results from in vitro mutagenicity
tests are followed up).
 There is no additional evidence based on physical chemical
properties, structure or use that the substance could be biolog-
ically active.
As adjusted therefore, this proﬁle was found for 21 substances
and held true in the 90-day study for 20 (95%) substances, with
one outlier being equivocal due to the large range of test doses
applied.
4.3. The ‘low toxicity’ substances
Statistically, there will always be a subset of substances with a
low toxicity proﬁle and while it is apparent in this dataset that
there is no single structural or physicochemical property of these
substances that would predict the proﬁle, the majority of sub-
stances did show properties which would indicate low toxicity.
For some of the substances, low toxicity can be explained by low
oral bioavailability which could have been predicted as a conse-
quence of solubility or molecular weight (e.g. EC 213-879-2; EC
221-424-4; EC 500-183-1, EC 232-482-5); others could be pre-
dicted to be subject to rapid metabolism and/or urinary excretion,
with limited systemic exposure (e.g. EC 619-383-6); others are
naturally occurring dietary components (e.g. EC 211-519-9) and
therefore already known to be of low toxicity. For some substances,
however, limited testing appears to have been necessary to deter-
mine the toxicity proﬁle. It is therefore premature to suggest struc-
tures that could predict the low toxicity proﬁle.
4.4. Animal reduction possibility
Our analysis supports the HSE NONS review in that substances
with the low toxicity proﬁle tend to be of low prevalence among
general industrial chemicals. Within both datasets of substances
with both 28-day and 90-day study results the prevalence of low
toxicity is in the range of 10–15%. Prior to REACH, which now
requires a 90-day study as a standard information requirement
for high production substances, companies would perhaps have
made a scientiﬁc judgement that a 90-day study on a low toxicity
substance was not worthwhile. Therefore the ‘low toxicity proﬁle’
could be higher in the real world.
Given the thousands of substances to be registered under
REACH, non-conduct of approximately 15% of 90-day oral studies,
however, could still achieve a signiﬁcant reduction in cost and ani-
mal usage, without compromising human health protection. On 1st
June 2013, a further 2923 substances were registered as being
manufactured or imported in quantities of 100 tonnes or more
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require a 90-day study if one has not already been performed or
can be waived. The 90-day study uses a minimum of 100 animals
and costs an estimated 116 k Euros (Fleischer, 2007). Non-conduct
of the 90-day study for 15% of these substances would therefore
result in a saving of 43845 animals and cost reductions of over
50 million Euros. Serious consideration of the added value of the
conduct of the 90-day study for substances with a ‘low toxicity
in a high quality dataset’ would align with one of the policy aims
of REACH to minimise animal testing and to promote alternative
methods of obtaining data. It has the added beneﬁt of reducing
the costs for registration.
4.5. How to waive the 90-day test in REACH registrations
Two independently conducted reviews of different substances
have now concluded that a ‘low (sub)acute toxicity proﬁle’ is pre-
dictive of low toxicity in the sub-chronic 90-day oral study in rats.
Substances that appear to ﬁt the proﬁle should be seriously consid-
ered as candidates for waiving the 90-day study under REACH (or
indeed any other regulatory regime for that substance). Column 2
of Annex IX 8.6.2 already permits the waiving of the 90-day study
if ‘‘the substance is unreactive, insoluble and not inhalable and
there is no evidence of absorption and no evidence of toxicity in
the 28-day ‘limit test’, particularly if such a pattern is coupled with
limited human exposure’’. This is a high hurdle to clear and not all
the substances included in this review would meet this deﬁnition.
There may be particular difﬁculty, for example, in demonstrating
limited human exposure or lack of absorption. We suggest that
REACH registrants will have to use Annex XI Section 1.2 ‘weight
of evidence’ arguments in their submission, referring not only to
the ’low (sub)acute toxicity in a high quality dataset’ proﬁle and
analysis presented here but to substance-speciﬁc arguments that
support this. This may include the results of other existing sub-
acute or sub-chronic tests, the results of (Q)SARs, whether the sub-
stance is ‘natural’, and whether its structure and physicochemical
properties already give conﬁdence that the substance is not bio-
available. In vitro absorption tests could also support the waiving
of the test if the suspicion is that the substance is unreactive due
to lack of absorption (e.g. in vitro skin absorption OECD TG 428,
OECD, 2004 and in vitro gastrointestinal absorption methods using
Caco-2 cells, see van Breemen and Li, 2005). In the meantime we
strongly urge ECHA and the European Commission to consider
the implications of this survey and that of the HSE NONS review,
issue guidance and adjust the REACH Annexes, which appear
overly-strict in this respect.
4.6. Limitations of the survey
A limitation to both this study and the HSE NONS review is that
the review was not done blind. That is, we had awareness of the
result of the 90-day study at the point of making the comparison.
This is because we had to be sure that we had 90-day studies of
sufﬁcient quality to enter into the dataset. In addition, because of
the way the data is presented in the ECHA CHEM database the per-
son reviewing the data could see all the test results. We have been
transparent in our treatment of the data but future analyses should
seek to test our ﬁnal criteria ‘blinded’ and follow as much as pos-
sible the principles of (retrospective) ‘validation‘, described by
the OECD (OECD Guidance Document 34, OECD, 2005). One way
to do this would be to ensure that one person creates the database
of substances, removes the 90-day study information so that a sec-
ond person can make predictions based on the criteria developed
here, and then compares these to the results of the 90-day studies
that have been veriﬁed by a third person who is unaware of all
other information.An element of expert judgment will always be required to
determine whether the substance ﬁts the ‘low (sub)acute toxicity
in a high quality dataset’ proﬁle. This is because it is necessary to
check the (robust) study summary to ensure that the registrant
was correct to come to the conclusion they did on the acute toxic-
ity test results and the results of the 28-day study. There is always
an element of opinion on whether some ﬁndings are biologically
relevant or can be dismissed. It may be that for some substances
the NOAEL from the 28-day should be adjusted. In addition, there
is other information on the substance that should be considered,
such as its use, structure, physical chemical properties and any
other test results, if available, that would enable the expert to
explain why the substance may be of low toxicity.
Studies that used excessively large doses in the top group sig-
niﬁcantly affected our ability in some cases to come to a conclusion
about low toxicity, including for the one remaining outlier. Because
of the wide dose ranges either side of the limit dose (deﬁned as our
cut off for ‘low toxicity’) the NOAEL was sometimes lower than
1000 mg/kg bw/d, since effects were (unsurprisingly) seen at the
top dose. In this way the test led to a conservative NOAEL. Had
the study been conducted up to the limit dose it is entirely feasible
that several of the substances would have a NOAEL of 1000 mg/
kg bw/d. The use of doses in excess of the limit is of general con-
cern aside from this survey. Excessive doses have animal welfare
implications in that (severe) adverse effects will almost certainly
be experienced. They are also unnecessary as excessive doses usu-
ally result in effects of no relevance to the human risk assessment
since such (relative) exposures in humans will never be seen. Inter-
nationally agreed OECD test guidelines for both the 28-day and the
90-day oral study permit the use of the limit dose to avoid the use
of excessive doses unless human exposure indicates the need for a
higher dose level to be used.
4.7. Scope of the recommendation
The MSC expressed concern about the use of old studies in the
HSE NONS analysis, even though this did not inﬂuence the results
(ECHA, 2011). Their concern was that the original OECD TG407 (the
key, oral route, 28-day guideline, OECD, 2008) was created in 1981
and revised in 1995 to include more parameters and therefore that
studies conducted prior to these dates would not be so sensitive.
However, the fact that the prediction model works with old data
actually strengthens it, since if old 28-day studies are not very sen-
sitive then there are in theory less likely to predict the 90-day
result, whereas they predict low toxicity in the 90-day study very
well. What is important in the reviews demonstrating the validity
of the ‘low toxicity proﬁle’ is that the 90-day study (TG 408, OECD,
1998) is conducted to modern standards, not necessarily the
28-day study. Nonetheless we responded to the MSC concerns by
omitting studies that at least predated the creation of the OECD
TG (i.e. studies older than 1981) and ensuring high quality (Kli-
misch) scores for both 28-day and 90-day studies.
It does appear that those substances with a low (sub)acute tox-
icity proﬁle are of generally low toxicity in all other toxicity tests.
Further analysis identiﬁed no additional hazards for these sub-
stances (e.g. carcinogenicity), giving conﬁdence that relevant
effects are not being missed by the non-conduct of the 90-day
study. Indeed, since our analysis found that the 90-day study for
these substances also gave a NOAEL of close to 1000 mg/kg bw/d
then clearly the 90-day study did not identify any ﬁndings of con-
cern that would warrant further investigation in chronic or carcin-
ogenicity studies.
However, it should be noted that the recommendation to waive
testing is currently limited to the 90-day study only and does not
extend to reproductive studies such as the reproductive toxicity
screening study, the prenatal developmental toxicity study or the
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ductive toxicity screening study (TG 421, OECD, 1995) is a require-
ment of Annex VIII, the same point at which the 28-day study is
considered and prior to consideration of the need for a 90-day
study (see Table 1). For substances for which a 90-day is manda-
tory (Annex IX), a prenatal developmental toxicity test is also
mandatory, so reproductive concerns would need to be considered
– separately – at the same stage anyway. A two-generation repro-
ductive toxicity test is required if effects on reproductive tissues
are seen in either the 28-day or 90-day test. Since both 28-day
and 90-day tests look at the reproductive tissues, only one of these
is needed. A two generation reproductive toxicity test is also
required at Annex X, irrespective of the presence or absence of
any alerts. So, the non-conduct of the 90-day study should there-
fore really have no bearing on the consideration of reproductive
effects.
Two substances used in this study are, however, of concern
within the REACH context. EC 247-148-4 is on the candidate list
for persistent, bioaccumulative and/or toxic (PBT) concerns,
namely bioaccumulation; EC 284-366-9 is on the Community
Action Rolling Plan list for its environmental PBT properties. In
the context of REACH, persistence, bioaccumulation, reproductive
and ecotoxicity concerns would be identiﬁed in other tests and
therefore have no impact on the applicability of this approach.4.8. Extending the proﬁle using other data
When sufﬁcient data becomes available it would be interesting
to see if the low toxicity rule applies to tests conducted via the der-
mal and inhalation routes in addition to the oral route. We
repeated the review using inhalation as the route and found that
only 3 out of 71 gases and vapours with both studies satisﬁed
the criteria for low toxicity in a high quality dataset (diﬂuorome-
thane, EC 200-839-4; 1,1,1,2,2-pentaﬂuoroethane, EC 206-557-8;
1,1,1-triﬂuoroethane, EC 206-996-5). All of these also showed no
toxicity at the equivalent limit in the 90-day study by the inhala-
tion route. We did not include them in this survey since the inha-
lation and dermal routes are complicated by site of contact effects
as well as systemic toxicity. However, these initial ﬁndings suggest
that the rule may also apply to the inhalation route but we appre-
ciate that more data may be required.
Substances with results for the combined repeated dose/repro-
ductive toxicity screening study (OECD TG 422, OECD, 1996)
instead of the 28-day study (OECD TG 407) were not included
in this analysis. A reproductive toxicity screening study (TG421)
is a requirement of Annex VIII, the same point at which the 28-
day study is considered (see Table 1). In this scenario, TG 422 is
a useful animal reduction method. In the combined study males
are dosed for at least 4 weeks and females longer, about 53 days.
So the dosing length is equivalent to the 28-day study. It is pos-
sible therefore that the same rule may apply to a negative OECD
422 result. However, largely due to our desire to keep the analy-
sis simple and the complicating fact that TG422 studies tend to
be recorded as reproductive toxicity studies, necessitating an
entirely separate eChemPortal search, we cannot make this judge-
ment at this time.
We also restricted the database to only rat data to avoid the
complication of species differences. Both the 28-day and the
90-day study tend to be conducted on rats; however there are
occasions when mice are used. Some of the substances also had
non-rodent data, shown in Table 2. It may be worthwhile expand-
ing the dataset to any 28-day or 90-day test result but this would
be for the purposes of expanding the dataset upon which to test
the hypothesis only, as most substances would have rat data if they
had any data at all.4.9. Suggestions for future investigations
Given the apparently low prevalence of low toxicity substances
with both 28 and 90-day study results, the proﬁle is currently
demonstrated with a low number of substances. Clearly the difﬁ-
culty lies in obtaining databases of substances that have good qual-
ity data from both the 28-day and 90-day studies and show low
toxicity.
Databases of cosmetics may be a good source of non-toxic sub-
stances, however, the EU based CosIng (see http://ec.europa.eu/
consumers/cosmetics/cosing/) is not a complete toxicological
database. The opinions of the European Commission’s Scientiﬁc
Committee for Consumer Safety (see http://ec.europa.eu/health/
scientiﬁc_committees/consumer_safety/opinions/index_en.htm),
which include study summaries, are usually on substances with
potential toxicity issues. Another option may be the REACH Annex
IV substances, of which there are over 30, which are substances
that do not need to be registered due to no toxicological activity
and include naturally occurring substances such as glucose and
neon. REACH consortia that may have unused data or data on sub-
stances not yet registered are also encouraged to come forward
with more data.
Following the submission of the Annex IX substances in June
2013, however, it is likely that the ECHA CHEM database will soon
be populated with more substances that have both 28-day and 90-
day study results. One recommendation is therefore to redo the
analysis on substances not yet used in this or the HSE NONS study,
using the criteria developed here. It could be broadened to allow
the results of the combined repeated dose/reproductive toxicity
screening study (TG422) to be considered in addition to the
28-day study. In addition, rather than focusing on the low toxicity
proﬁle alone, it may be of interest to quantitatively correlate the
NOAELs of all substances with both 28 and 90-day study results.
Although it is generally assumed that the NOAEL decreases with
increasing study duration, to date there has been no statistical
analysis of this using a large dataset of industrial chemicals. This
could help conﬁrm the ‘low (sub)acute toxicity rule’ as well as pro-
vide information on the overall relationship between the 28 and
90-day study. This would be similar to the study by Bulgheroni
et al. (2009) that looked at the relationship between the acute oral
toxicity test and the 28-day study in an effort to see if the NO(A)EL
in the 28-day study could retrospectively predict toxicity in the
acute study.
4.10. Prediction of results from substances with 90-day studies
proposed
Another way to test the ‘low toxicity’ hypothesis is to make a
prediction of the 90-day study result immediately before it is con-
ducted. It is better in terms of animal welfare to avoid this kind of
prospective validation but this scenario already exists as a conse-
quence of the testing proposal system under REACH. From the ﬁrst
REACH deadline, by 1 September 2012 there were 114 substances
that had testing proposals on the ECHA website for the 90-day
study rather than submission of the data itself. We reviewed this
dataset and identiﬁed 14 substances (12%) that appeared to ﬁt
the ‘low toxicity proﬁle in a high quality dataset’ proﬁle (see
Table 3). These substances were then reviewed by one of the
authors (Andrew) to apply a level of expert judgment to the
reported results. They made a ﬁnal conclusion that for 11 sub-
stances they would expect a 90-day study result to also be around
1000 mg/kg bw/d; three they were unsure about. The delay to the
submission of this paper was done so as not to appear to be inter-
fering with the decision making by the MSC on these substances, a
process which typically takes at least a year. The test results of this
sample will not be known until the end of 2014, but, should they
Table 3
Substances with 90-day studies proposed by 1 Sep 2012, ﬁtting the low toxicity proﬁle.
EC No. 28 day result,
rat, oral
Skin
sensitisation
Acute toxicity, oral Skin
irritation
Eye
irritation
Mutagenicity
–
in vitro
Mutagenicity
–
in vivo
Comments
480-370-1 (2007) NOAEL = 1000 mg/kg bw/d N/A LD50 > 2000 mg/kg bw Not
irritating
Some
evidence
of
irritation
Positive/
negative
Negative The low water solubilit of this substance may limit oral bioavailability.
Data indicate rapid hyd lysis (<1 min) to form ethanol and polymeric
reaction products, so an systemic absorption is likely to be due to ethanol
432-070-7 (2000) NOAEL = 1000 mg/kg bw/d Not
sensitising
LD50 > 2000 mg/kg bw Not
irritating
Some
evidence
of
irritation
Positive/
negative
Negative Some effects seen in the 8-day study at the limit dose of 1000 mg/kg bw/d,
but these were not cons ered to be of toxicological signiﬁcance and/or not
clearly related to treatm nt
470-680-5 (2008) NOAEL = 1000 mg/kg bw/d
kg/day, (2007) NOAEL = 1000 mg/
kg bw/d
Not
sensitising
LD50 > 2000 mg/kg bw Not
irritating
Irritating,
category
2
Negative Not done Two 28-day studies; on with minor/adaptive effects at the highest dose
level of 1000 mg/kg bw ; a second study performed at 2000 mg/kg bw/d
shows effects on some arameters but these are disputed by an
independent reviewer ( ut in any case are above the limit dose). UNSURE
204-111-7 (1995) NOAEL = 1000 mg/kg bw/d Not
sensitising
LD50 = 2900 mg/kg bw Not
irritating
Slightly
irritating
Negative Negative Evidence of adaptive eff cts at the highest dose level of 1000 mg/kg bw/d in
the 28-day study and r al effects in the male rat (only) are dismissed as
non-relevant; justiﬁcat n for low toxicity would require a more detailed
case for dismissing the effects. UNSURE
230-991-7 (1990) NOAEL = 1000 mg/kg bw/d,
NOEL = 200 mg/kg bw/d
Not
sensitising
LD50 = 4595 mg/kg bw –
practically nontoxic
Not
irritating
Highly
irritating
Negative Not done Minor/reversible effects een at the highest dose level of 1000 mg/kg bw/d
in the 28-day study. NB ubstance is shown to cause developmental toxicity
at dose levels not causi g maternal toxicity
203-326-3 (2010) NOAEL = 1000 mg/kg bw/d,
NOEL = 300 mg/kg bw/d
Not
sensitising
LD50 > 2000 mg/kg bw Not
irritating
Not
irritating
Negative Not done No effects of treatment t the limit dose of 1000 mg/kg bw/d in the 28-day
study. OECD QSAR Tool ox predicts no bioavailability which would be
consistent with the mo cular weight and insolubility in water
211-074-0 (1995) NOAEL = 1000 mg/kg bw/d Not
sensitising
LD50 = 3000 mg/kg bw –
practically nontoxic
Not
irritating
Not
irritating
Negative Not done Substance predicted to e bioavailable but rapidly metabolised and
incorporated into norm l metabolism
203-838-7 (1998) NOAEL = 1750 mg/kg bw/d Not
sensitising
Exp NS: LD50 = 8370 mg/
kg bw – practically nontoxic
Corrosive
–
category
1
Exp NS:
highly
irritating
Negative Not done Substance is classiﬁed f r acute inhalation toxicity (borderline) but this is
likely to be related to it corrosivity. Toxicity was seen at the highest dose
level of 3500 mg/kg bw in a 28-day study; effects are most likely related
to local irritation caused y gavage. NOAEL of 1750 mg/kg bw/d exceeds the
limit dose. Substance is xpected to be absorbed and rapidly metabolised
(fatty acid)
426-040-2 (1997) NOAEL = 1000 mg/kg bw/d Not
sensitising
LD50 > 2000 mg/kg bw Not
irritating
Not
irritating
Negative Not done No effects at the limit d se; substance not predicted to be bioavailable
based on the molecular eight and low water solubility
641-136-6 (2010) NOEL = 1000 mg/kg bw/d,
no NOAEL identiﬁed
Not
sensitising
LD50 > 2000 mg/kg bw Not
irritating
Not
irritating
Negative Not done No effects at the limit d se of 1000 mg/kg bw/d in the 28-day study; the
substance is likely to b of limited or no bioavailability based on its low
water solubility
271-237-7 (2010) NOAEL = 1000 mg/kg bw/d
in females and 300 mg/kg bw/d in
males
Not
sensitising
LD50 > 2000 mg/kg bw Not
irritating
Not
irritating
Negative Not done 28-day reports a NOAE of 300 mg/kg bw/d in males, apparently based on
reduced weight gain. Ot er effects at the highest dose level are dismissed as
adaptive or non-advers Substance is a UVCB and only a proportion of the
components are likely t be bioavailable. However, the NOAEL in males
cannot be disregarded. NSURE
271-239-8 (2010) NOAEL = 1000 mg/kg bw/d
in females and 300 mg/kg bw/d in
males
N/A LD50 > 5000 mg/kg bw Not
irritating
Slightly
irritating
category
2B
Negative Not done 28-day NOAEL of 300 m /kg bw/d for males based on a marginal effect on
red blood cell paramete s (increased erythrocyte count – not adverse?) at
the highest dose level o 1000 mg/kg bw/d
404-370-8 (1995) NOAELP 1000 mg/kg bw/d Not
sensitising
LD50 > 2000 mg/kg bw Irritating Not
irritating
Negative Not done Effects at the limit dose f 1000 mg/kg bw/d in the 28-day study are
minimal/adaptive. The tact substance is unlikely to be bioavailable,
however systemic expo re to the hydrolysis product is likely (hydrolysis at
pH 4 is very rapid)
402-140-1 (1996) NOAELP 1000 mg/kg bw/d Not
sensitising
LD50 > 2000 mg/kg bw Irritating
– cat 2
Not
irritating
Negative/
positive
Negative Effects at the limit dose f 1000 mg/kg bw/d in the 28-day study are
minimal/adaptive. The tact substance is unlikely to be bioavailable,
however systemic expo re to the hydrolysis product is likely (hydrolysis at
pH 4 is very rapid)
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332 K. Taylor et al. / Regulatory Toxicology and Pharmacology 69 (2014) 320–332support our hypothesis then this should give signiﬁcant weight to
the validity of the ‘low toxicity proﬁle’ approach.
5. Conclusion
A review of the ECHA CHEM database identiﬁed 18 substances
with a ‘low toxicity’ result in the 28-day study and no reports of
toxicity in other acute tests. Of these substances, 16 (89%) also
showed no signs of toxicity at, or close to, the limit dose of
1000 mg/kg bw/d in the 90-day study. The conclusion therefore
is that if a substance conforms to a number of criteria indicating
a ‘low (sub)acute toxicity proﬁle’ then the 90-day study may be
redundant. Based on our analysis we would recommend that sub-
stances with only skin or eye irritation are not excluded from the
‘low toxicity proﬁle’ since these substances appear to also show
low toxicity in the 90-day study, but that substances that, based
on their use or existing knowledge, are known to be biologically
active should be excluded. Our suggestion is that substances are
considered for this approach if they satisfy ALL of the following
criteria:
 Experimental data equivalent to OECD test method TG 407, on
the substance itself, conducted 1981 or later, with reliability
score 1 or 2 and conducted to the limit dose (1000 mg/kg bw/
d) or higher, with a study result reported to be a NOAEL of
1000 mg/kg bw/day or higher.
 The substance is not reported to be mutagenic or a skin sensitis-
er or acutely toxic by any route and there are adequate data to
support this (i.e. any positive results from in vitro mutagenicity
tests are followed up).
 There is no additional evidence based on physical chemical
properties, structure or use to suggest that the substance could
be biologically active.
Retrospectively, this low toxicity proﬁle was found for 21 sub-
stances and held true in the 90-day study for 20 of these (95%),
with the remaining substance being equivocal due to the large
range of test doses applied. Avoidance of redundant 90-day studies
for the remaining phase-in REACH substances could collectively
avoid the use of nearly 50,000 animals and save industry 50 mil-
lion Euros. Regulatory authorities and chemical companies must
now consider if the 90-day study can be waived on a case by case
basis for individual chemical substances on the basis of this ‘low
toxicity with high quality data’ proﬁle.
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